ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORMP vs ANTX // DIVIDEND YIELD & FCF PAYOUT SAFETY

Oramed Pharmaceuticals Inc. (NASDAQ) VS. AN2 Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ORMP 3 — ANTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORMP VS. ANTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORMP ANTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 0.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -7.80% -35.00% +27.20 ORMP /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.20% -16.86% +11.66 ORMP /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 3.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 35.7 50.0 -14.30 ANTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $166.4M $164.2M $2.2M ORMP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORMP REV ANTX REV ORMP GROSS % ANTX GROSS % ORMP FCF ANTX FCF
FY 2025 $2.0M $106.7M 0.7% — -$9.2M -$29.8M
FY 2024 $35.8M $159.0M — — -$8.4M -$49.3M
FY 2023 $1.3M $195.0M — — -$10.3M -$53.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORMP // BETA —
ANTX // BETA —